# SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC

> **NCT07701070** · — · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 3000 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **OTHER:** Blood sampling

## Key facts

- **NCT ID:** NCT07701070
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2029-03-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701070, "SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07701070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*